FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival

ABSTRACT Background FXYD3 is a Na/K‐ATPase modulator which is upregulated in pancreatic ductal adenocarcinoma (PDAC), but its prognostic role is unknown. This study evaluated FXYD3 expression in chemo‐naive patients with surgically‐resected PDAC at a single centre (1993–2014). Method FXYD3 expressio...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Nathalie B. Rasko, Christopher B. Nahm, John Turchini, Rachel Teh, Helge Rasmussen, Sooin Byeon, Sumit Sahni, Jaswinder S. Samra, Anthony J. Gill, Anubhav Mittal
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2025-01-01
Edice:	Cancer Medicine
Témata:	FXYD3 MAT‐8 pancreatic cancer pancreatic ductal adenocarcinoma prognosis survival
On-line přístup:	https://doi.org/10.1002/cam4.70500
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!